Health Care • Medicinal Chemicals and Botanical Products
$6.71 ▼ -0.15
(-2.19%)
MKT CAP: $3.40B • VOL: 148.2K
52W L $5 52W H $69
ROARABLE / RQD
D- • 38/100
PIOTROSKI
2 / 9
RGC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$3.8M | -$4.7M | -$6.3M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$3.6M | -$4.3M | -$5.9M |
| EBITDA (Normalized) | -$3.6M | -$4.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$3.1M | -$4.0M | -$5.0M |
| Capital Expenditures (CapEx) | $152.7K | $5.4K | — |
| Free Cash Flow (FCF) | -$3.3M | -$4.0M | -$5.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | — | — | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | — | — | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RGC.